GCM
RPRX icon

Gladius Capital Management’s Royalty Pharma RPRX Stock Holding History

Gladius Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,208
Closed -$31.9K – 347
2024
Q2 		$31.9K Buy
+1,208
New +$33.5K ﹤0.01% 229
2022
Q3 		– Sell
-932
Closed -$40K – 484
2022
Q2 		$40K Sell
932
-2,737
-75% -$112K ﹤0.01% 276
2022
Q1 		$143K Buy
+3,669
New +$144K 0.01% 190

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gladius Capital Management's RPRX Position: Q3 2024 in Review

Gladius Capital Management sold out of Royalty Pharma (RPRX) in Q3 2024, closing a stake of 1,208 shares — an estimated $31.9K sold.

Gladius Capital Management first reported a position in RPRX in Q1 2022 and held it in 3 quarters. The position peaked at $143K in Q1 2022. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

  • Gladius Capital Management reported no remaining Royalty Pharma position as of Q3 2024 after selling out during the quarter.
  • Gladius Capital Management sold 1,208 Royalty Pharma shares in Q3 2024, an estimated $31.9K.
  • Gladius Capital Management first reported a position in Royalty Pharma in Q1 2022 and held it in 3 quarters.
  • Gladius Capital Management's Royalty Pharma position peaked at $143K in Q1 2022.
  • 395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on Gladius Capital Management's 13F filing for Q3 2024, filed 6 Nov 2024.